You have read all your free articles, to continue reading subscribe to read the rest of this content.
Patent, pricing, production, and partnerships – these are the four Ps that companies must keep front and center for a successful market entry. Orexo’s CEO Nikolaj Sørensen answers some questions about how his company addressed these aspects when Orexo entered the US market. Although Orexo haAlready a subscriber Login You…
Eir Ventures, a Nordic life science venture fund, has announced a first close of its new fund of EUR 76 million. With a base in the Nordic region and a team of experienced life science investors, Eir Ventures will invest in innovative companies with products and technologies addressing significanAlready a…
Thanks to the potential for higher prices, limited competition and favorable regulations, orphan drugs continue to be popular to manufacture and also attractive to buy, and Moody’s predicts they will continue to generate merger and acquistion activity. Nearly half of recent acquisitons involvedAlready a subscriber Login You have read all…
Life science and biotechnology companies require a steady stream of capital and more are entering the stock exchanges to increase their visibility and find investors. NASDAQ Nordic is now one of Europe’s largest biotech hubs, according to Carsten Borring, head of listings and capital markets Already a subscriber Login You have read…
